|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||28.54 - 30.06|
|52 Week Range||17.90 - 43.93|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||206.78|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PetIQ CEO Cord Christensen tells Jim Cramer that 50 percent of pets in America do not have health care and explains what his company is doing to close the gap.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.
Perrigo Co. said Thursday that it has reached an agreement to acquire privately-held oral care company Ranir Global Holdings LLC in a $750 million all-cash deal, or $685 million including cash tax benefits. The announcement is part of a transformation strategy that the self-care company unveiled during its investor day event. Ranir's portfolio includes more than 300 oral care items including manual toothbrushes, floss and dentures. The deal is expected to be about 10 cents per share accretive to 2019 adjusted earnings based on a third-quarter closing. The move is part of Perrigo's strategy to grow in self-care adjacent areas of business, according to a statement from Chief Executive Murray Kessler. Ranir has 650 employees and generated $287 million in net sales in 2018. Annual operating synergies between the two companies are expected to be about $10 million by 2021. The company also reaffirmed its plans to sell or spin off the generic pharmaceuticals business by the end of 2019 or in 2020; divest the animal health business through a $185 million cash deal with PetIQ Inc. ; investing more than $250 million in incremental capital over the next four years to expand the infant nutrition and tablet manufacturing businesses; and launching a cost savings program that will generate $100 million in annualized cost savings. Perrigo is also in discussions with several cannabidiol (CBD) companies to create products, among other innovations the company is pursuing. For 2019, Perrigo is guiding for sales between $4.6 billion and $4.7 billion, EPS between $1.24 and $1.54, and adjusted EPS of $3.65 to $3.95. The FactSet consensus is for sales of $4.7 billion and EPS of $4.14. Perrigo shares are up 27% for the year to date while the S&P 500 index has gained nearly 15%.
The Eagle, Idaho-based company said it had profit of 7 cents per share. Earnings, adjusted for non-recurring costs, came to 27 cents per share. The results exceeded Wall Street expectations. The average ...
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]
PetIQ (PETQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares of PetIQ Inc. plunged 13.1% in morning trade Tuesday, putting them on track for their worst one-day performance since going public in July 2017, after short seller Spruce Point Capital said it believed the stock could fall as much as 90%. Spruce said PetIQ occupies "a murky space" in the pet pharmaceuticals market, in which the non-veterinarian distributors, such as PetIQ, buy excess prescription and over-the-counter product from veterinarians then sell them to retail customers. "Manufacturers are increasingly beginning to bypass the grey market and sell directly to retail...showing cracks in PetIQ's economic ecosystem," Spruce wrote in a research note. "Wider competition in the pet medicine distribution space and greater transparency into distributor margins among retailers could bring PetIQ product segment operating margins--8%-9% as of today--closer to the 1%-3% margins shown by other pharmaceutical distributors." PetIQ did not immediately respond to a request for comment. Spruce also said there appeared to be "suspicious circumstances" around PetIQ's acquisition of VIP Petcare completed in January 2018, and said earnings quality has been "poor." The stock has climbed 18.5% over the past 12 months while the S&P 500 has gained 10.7%.
For his "Executive Decision" segment of Mad Money Wednesday night, our own Jim Cramer spoke with Cord Christensen, chairman and CEO of PetIQ Inc. Christensen explained that his company is trying to make health care for your pet more accessible. In addition to selling items like flea and tick care through mass market retailers, PETQ also plans to operate 1,000 vet clinics over the next five years.
Today was shaping up to be a bone-crushing session on Wall Street, Jim Cramer told his Mad Money viewers Wednesday. Without one, it will be a lot harder to own sectors like the industrials that need a strong global economy. Cramer explained that President Trump is taking a page from the Ronald Reagan playbook with Russia, "trust, but verify." The Chinese have a long history of not abiding by what they agree to, he said, which was evident most recently in the South China Sea.
PetIQ Inc (NASDAQ:PETQ) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
While PetIQ, Inc. (NASDAQ:PETQ) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. But that doesn'tRead More...
PetIQ (PETQ) delivered earnings and revenue surprises of -14.29% and 12.46%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Eagle, Idaho-based company said it had a loss of 16 cents. Earnings, adjusted for non-recurring costs, came to 6 cents per share. The results did not meet Wall Street expectations. ...
On Monday, March 11, PetIQ (NASDAQ: PETQ ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue PetIQ earnings ...
Over the weekend, the shares of pet healthcare company PetIQ (NASDAQ:PETQ) lost nearly 10% of their value after Raymond James analyst Joseph Altobello lowered his price target on PetIQ stock to $39 per share from $42 per share.Despite the fact that Altobello maintained his "Outperform" rating and cautioned investors not to completely abandon the shares, PetIQ stock had plunged to $27.30 per share this morning, a significant discount from the firm's 52 week high of $43.93. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Worries OverdoneWhile Altobello's remarks certainly weren't complimentary to PetIQ stock, were they bad enough to warrant the steep decline that PETQ stock suffered? * 7 Chinese Stocks to Buy for the 2019 Rebound Raymond James still believes that PETQ will deliver double-digit- sales and earnings growth over the next few years and the firm is expecting PetIQ's net sales to surge 18% in 2019. Altobello revised his price target on PetIQ stock to correct an earlier estimate that he believed was too optimistic; at the time of the revision, the new price target was more than 25% above the price of PETQ stock. Opportunity is KnockingNow that PETQ is trading for $27.4 per share, that price target looks even better as it is more than 40% above the current price of PetIQ stock. The company is due to release its fourth-quarter and full-year results next week, and as long as those figures are in-line with expectations, PETQ stock should pop. There's a lot to like about PetIQ right now. By selling directly to pet owners products and services for pets that used to only be available only through veterinarians, PETQ has entered a unique niche. The firm has grown substantially, and it now has nearly 3,000 veterinary clinics around the country. Management believes that the company can continue to expand. The firm says its addressable market in the U.S. is around $41 billion, meaning there is plenty of room for growth in the country in the years to come. What to ExpectIf PetIQ's Q4 results at least meet expectations next week, investors can expect PetIQ stock to rally. After posting strong Q3 results, management upped its full-year guidance. The company is expecting 2018 net sales of $515 million, a 93% increase from the previous year. Even more impressive is the company's guidance for adjusted EBITDA,which management is expecting to come in between $40 million and $45 million, an increase of between 79% and 102% from the previous year.Of course, those are just estimates and there's a chance the firm could miss its guidance, but based on the strong results that the company posted for the first three quarters of 2018, its guidance looks achievable. The Acquisition of VIP PetcareIn January, PETQ completed its strategic acquisition of VIP Petcare, a network of community clinics and wellness centers for animals. That purchase is expected to help PetIQ continue opening more clinics and retail locations in the U.S.. The deal cost PetIQ $100 million in cash, $30 million in promissory notes and about $90 million worth of stock. PetIQ was forced to take on $75 million in new debt in order to make the purchase, but most agree that the addition of VIP Petcare will benefit PETQ over the long-term.The purchase shouldn't impact PETQ's upcoming earnings, but the owners of PETQ stock will be interested in hearing how management expects the acquisition to impact the current quarter and when synergies from the deal will be realized. The Bottom Line on PetIQ StockPetIQ stock is the victim of a jittery market and fickle traders. The price target reduction by Raymond James should have raised a few eyebrows, but the decline of the stock has been overdone.PETQ is well-positioned to continue to grow over the next few years. As pets become more important to U.S. households, their care is likely to be one of the last items people will stop spending money on if the economy turns sour. I expect PetIQ to report positive earnings, enabling PETQ stock to bounce back towards $30 per share.As of this writing, Laura Hoy did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Big Data Stocks That Deserve a Closer Look * 7 Best Energy Funds to Outperform the Market * 5 Blue-Chip Stocks Ready to Rise Compare Brokers The post Should You Buy the Dip of PetIQ Stock? appeared first on InvestorPlace.
PetIQ Inc. (NASDAQ: PETQ ) shares fell sharply Monday as at least one analyst adjusted earnings expectations for the pet health products company and lowered stock price expectations. The Analyst Raymond ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]
PetIQ (PETQ) delivered earnings and revenue surprises of 88.00% and 5.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Eagle, Idaho-based company said it had profit of 13 cents. Earnings, adjusted for non-recurring costs, were 47 cents per share. The results surpassed Wall Street expectations. ...